Stockreport

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript [Seeking Alpha]

Xilio Therapeutics, Inc.  (XLO) 
PDF Company Participants Ruth du Moulin Rene Russo - President, CEO & Director Katarina Luptakova - Chief Medical Officer Christopher Frankenfield - CFO & COO Con [Read more]